Business Wire

NEP-GROUP

16.2.2024 09:16:29 CET | Business Wire | Press release

Share
NEP Appoints Lise Heidal as President, NEP Broadcast Services Europe

NEP Group, the leading worldwide media technology partner for live sports and entertainment, announced today that Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services, effective 1 April. Based in Norway, Heidal will set the strategy, priorities and focus areas for nine countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216806377/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Industry veteran Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services. She will set the strategy, priorities and focus areas for all countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses. (Photo: Business Wire)

With over 25 years of multifaceted experience in the media, telecom, and consulting industries, Heidal stands out as a pragmatic leader committed to driving operational excellence, business transformation and strategic innovation. Known as someone committed to building great teams with a genuine interest in the people she works with, Heidal’s approach combines strategic vision and operational expertise, whilst fostering a culture of accountability. Most recently she served 2,5 years as the VP of Production at TV 2, the largest commercial broadcaster in Norway. Prior to that, she served as Managing Director of NEP Norway and led several global NEP initiatives that achieved continuous development and profitable growth from 2010 to 2021.

As part of the new European leadership team, Christer Pålsson has been named Chief Commercial Officer for Europe, reporting into Heidal. As CCO, Pålsson will be responsible for all commercial and sales activities across the region and work closely with NEP’s global sales team to align strategy and execution, including for major events worldwide. He brings with him extensive experience in business leadership, sales, client service, partnerships and operations for NEP in the Nordics, Central and Southern Europe. Prior to joining NEP, Pålsson was Head of International Sales for Mediatec Broadcasting company, which became a part of NEP in 2015.

To support this transition NEP is also pleased to announce that Jose (Tex) Teixeira will join NEP on 4 April initially as President for NEP Nordics, Central & Southern Europe. Teixeira brings with him over 30 years of sport broadcast experience delivering world-class live productions in Africa and New Zealand. A creative, loyal and energetic individual with a can-do spirit, he has specialised in content strategy and acquisition, programming and production, leading large teams, building dynamic environments and managing strategic relationships with rights holders, federations and suppliers across multiple territories throughout his career. He most recently served as Chief Content Officer for SuperSport and as their Interim CEO in 2023.

Rounding out the European senior leadership team, Arjan van Westerloo and Steve Jenkins will continue in their current roles as President, NEP The Netherlands, and President, NEP UK & Ireland, respectively.

Mike Werteen, Global President of NEP Broadcast Services, said: “Combining our UK and European businesses under a single, dynamic and experienced leadership team is an exciting step forward. Having such a powerful group in place enables us to achieve our vision to be the leading global media services provider in live sports and entertainment. Under Lise’s direction, supported by the foundations that all European and UK team members have put into place, I’m confident we will be able to harness all of the talent, synergies, sales and employee career opportunities across these important markets.”

Lise Heidal said: "I am deeply honored to accept the position as lead of the NEP Broadcast Services European organization. It is a privilege to have the opportunity to work with a team of such dedicated and talented individuals. I am fully committed to enhancing our collaborative efforts across Europe, to serving our clients, and to continue building on our shared successes."

While continuing to manage the day-to-day business, the first priority for the European leadership team will be to drive increased collaboration and process improvements for the region as part of the company’s 2024 goals and longer-term plans.

For more information about NEP, visit www.nepgroup.com.

About NEP

You have a vision. We see it, too. With a worldwide network of experts and cutting-edge technology, our unique Global Production Ecosystem empowers content creators and rights holders to tell stories in breakthrough ways. We're built on 35 years of trusted experience across broadcast, live event, and virtual production to deliver the solutions you need—anytime, anywhere.

Headquartered in the United States, NEP has operations in 25 countries with over 5,000 employees. Together, we have supported productions in over 100 countries on all seven continents, and we’re still growing. Learn how we help our clients bring content to life at nepgroup.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240216806377/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye